HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence

This article was originally published in The Rose Sheet

Executive Summary

The agency will accept public comment for 60 days on its proposed survey to gain insight into “consumer use of cosmetic products, the frequency of adverse events believed to be caused by allergens in cosmetics, consumer awareness of the problem, and actions (if any) taken to avoid the allergens.”

You may also be interested in...



Industry Cautions FDA To Avoid ‘Overinterpreting’ Cosmetic Allergy Survey Results

In a March 5 statement, FDA Commissioner Scott Gottlieb included labeling disclosure of known cosmetic allergens among elements that could be included in a modernized system for cosmetics oversight. The agency’s planned consumer survey, designed to assess “allergy to cosmetics,” could help to inform exploratory steps in that direction.

FDA Contracts For QRA Model To Determine Safe Use Levels For 26 Fragrance Allergens

The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.

Cosmetics Adverse Events Under Spotlight In FDA Transparency Push

FDA’s release of AER data removes some secrecy surrounding cosmetic product adverse events but could create a false alarm about the industry. The data dump comes as Congress is considering legislation that would mandate that cosmetics firms provide FDA with reports of serious adverse events they receive.

Topics

UsernamePublicRestriction

Register

RS122416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel